GlassScriptPhysician profile
Kenny Hui
NPI 1588637540
$14,920.75
in general payments reported to CMS, 2019-2025
39 companies · $3,075 in 2025
The $3,075 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $935 · 2021: $1,855 · 2022: $2,219 · 2023: $2,945 · 2024: $2,758 · 2025: $3,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,608 · Education: $129 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,608.19 |
| Education | $129.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,636.29 | 2019-2025 | |
| Janssen Biotech, INC. | $2,230.63 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,020.75 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $824.54 | 2020-2025 | |
| Pfizer INC. | $776.88 | 2019-2025 | |
| Genzyme Corporation | $764.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $731.72 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $614.11 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $559.80 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $516.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $462.63 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ardelyx, INC. | $401.87 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $368.65 | 2021-2023 | |
| Qol Medical, LLC | $365.65 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $265.64 | 2019-2024 | Injectafer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $236.30 | 2019-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $138.82 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $134.89 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $125.92 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $120.58 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $72.11 | 2020-2025 | Sutab, Suflave |
| Celltrion USA INC. | $69.14 | 2024-2025 | Vegzelma |
| Lucid Diagnostics INC. | $66.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $55.13 | 2019-2023 | Cimzia |
| Intercept Pharmaceuticals, INC. | $54.58 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $53.23 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $38.81 | 2021-2022 | |
| Medtronic, INC. | $33.39 | 2021 | |
| Exact Sciences Corporation | $27.49 | 2025 | Cologuard Collection Kit |
| Vivus LLC | $21.80 | 2025 | Qsymia |
| W. L. Gore & Associates, INC. | $16.99 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.23 | 2023 | Exparel, Zilretta, Iovera |
| Romark Laboratories, Lc | $16.03 | 2019 | |
| Fresenius Kabi USA, LLC | $15.73 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.68 | 2024 | Cyltezo |
| Medtronic USA, INC. | $14.31 | 2019 | |
| Shionogi INC | $13.91 | 2019 | |
| Ucb, INC. | $12.44 | 2019 | |
| Allergan, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Hui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.